Ardelyx, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARDX research report →
Range $13 – $13
Price Chart
About the company
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets.
- CEO
- Michael G. Raab
- IPO
- 2014
- Employees
- 489
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on ARDX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $751.60M
- P/E
- -13.31
- Fwd P/E
- 15.77
- PEG
- -7.44
- P/S
- 1.61
- P/B
- 4.56
- EV/EBITDA
- -33.51
- Div Yield
- 0.00%
- Gross Margin
- 94.26%
- Op Margin
- -7.71%
- Net Margin
- -11.85%
- ROE
- -35.30%
- ROIC
- -7.82%
Latest fiscal year · YoY change
- Revenue
- $407.32M+22.1%
- Gross Profit
- $364.72M+28.9%
- Op Income
- $-40,977,000
- Net Income
- $-61,599,000-57.4%
- EPS
- $-0.26-52.9%
- OCF Growth
- +5.2%
- FCF Growth
- +4.0%
- 52W High
- $8.40
- 52W Low
- $2.80
- 50D MA
- $3.23
- 200D MA
- $5.01
- Beta
- 0.68
- RSI (14)
- 43
- Avg Volume
- 4.41M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Ardelyx posted 19% revenue growth in Q3, narrowed its loss, and reiterated full-year guidance while emphasizing IBSRELA execution, XPHOZAH resilience, and progress in its CIC pipeline program.· November 3, 2026
- Total product revenue rose to $125.5 million, up 19% year over year, led by IBSRELA’s 23% growth to $96.3 million.
- XPHOZAH revenue increased to $29.2 million, up 7% year over year, with paid prescriptions up 22%.
- Net loss narrowed to $700,000, and the company ended the quarter with $285.3 million in cash, cash equivalents and short-term investments.
- Management reaffirmed 2026 guidance: IBSRELA $350 million to $370 million, XPHOZAH $110 million to $120 million, and operating expenses below $500 million.
- The ACCEL Phase III CIC trial was fully enrolled ahead of schedule, with top-line results still expected in the second half of 2027.
Third-quarter 2026 total product revenue was $125.5 million, up from $105.5 million a year ago, for 19% growth. IBSRELA revenue was $96.3 million, up 23% year over year, and XPHOZAH revenue was $29.2 million, up 7% year over year. Gross profit margin was stated as greater than 95%, and net loss narrowed to $700,000 versus a net loss of $1 million in Q3 2025. For the quarter, R&D expense was $25.2 million and SG&A was $93.9 million. Cash, cash equivalents and short-term investments ended at $285.3 million. For full-year 2026, management reaffirmed IBSRELA revenue guidance of $350 million to $370 million, XPHOZAH revenue guidance of $110 million to $120 million, and operating expenses below $500 million. Management also reiterated its expectation to reach profitability in 2027.
Mike Raab said Ardelyx now has two first-in-class medicines, a strong patent portfolio and a strengthened financial position, and he framed the company’s near-term priorities as accelerating IBSRELA, maintaining XPHOZAH momentum, and building the pipeline. He was upbeat on IBSRELA demand, describing it as all-time high and saying the company is working to reduce payer friction through sales force expansion, a larger field reimbursement team, pharmacy network utilization, digital tools and a new DTC campaign. On XPHOZAH, he said the need remains high but the reimbursement environment is complex, and he signaled patience on reestablishing a longer-term framework until the TDAPA period is over and next year’s environment is clearer.
Sue Hohenleitner emphasized that IBSRELA continues to drive growth, while the company is translating revenue into financial progress. She highlighted the quarter’s 19% total revenue growth, greater than 95% gross margin, a narrowed net loss of $700,000, and cash of $285.3 million. She also pointed to discipline in spending, with R&D at $25.2 million and SG&A at $93.9 million, and said the company remains focused on profitability in 2027 and on keeping 2026 operating expenses below $500 million.
Analysts focused heavily on IBSRELA payer friction, prescription channel mix, and timing of any improvement from the expanded field reimbursement team and direct-to-consumer campaign. Management said there is no single fix, calling for a mix of FRMs, payer discussions, digital efforts, and thoughtful contracting, and stressed that any improvement should be gradual rather than a sudden inflection. On XPHOZAH, management said it is too early to reestablish a longer-term revenue framework because the TDAPA period is ending and the reimbursement backdrop remains unsettled. Management also said it would not quantify off-label CIC use, but argued that ACCEL’s full enrollment ahead of schedule supports physician interest in a potential CIC label expansion.
The bull case from this call is that both marketed products continue to grow, with IBSRELA still showing strong momentum and XPHOZAH adding to revenue despite a difficult reimbursement setting. Management sounded confident that commercial execution, payer-navigation efforts, and a new DTC push can support continued adoption, while the balance sheet and high gross margin give the company room to invest and move toward 2027 profitability.
The main risks are continued payer friction, uncertainty around how much the new initiatives will improve fulfillment and access, and the complexity of XPHOZAH’s reimbursement environment. Management also acknowledged that it cannot yet provide clear visibility on long-term XPHOZAH targets, that any IBSRELA improvement may be gradual, and that the company is still early in assessing the impact of DTC and pharmacy-network changes.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 85.8%
- Shares Outstanding
- 251.37M
- Float Shares
- 215.58M
of shares held by institutions
263 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 28.37M | ▲ 4.86M |
| Vanguard Group Inc | 18.98M | ▲ 610.16K |
| Rubric Capital Management LP | 16.20M | ▲ 14.34M |
| Millennium Management LLC | 13.90M | ▼ 3.94M |
| State Street Corp | 13.24M | ▼ 115.29K |
| Vanguard Capital Management LLC | 10.45M | ▼ 25.93K |
| Nomura Asset Management International Inc. | 9.55M | ▲ 1.38M |
| Janus Henderson Group Ltd. | 8.37M | ▼ 6.14M |
| Vanguard Portfolio Management LLC | 7.98M | ▼ 46.00K |
| Geode Capital Management, LLC | 6.20M | ▼ 199.00K |
| Jupiter Topco LLC | 5.30M | ▲ 5.30M |
| Two Sigma Investments, LP | 5.21M | ▲ 935.78K |
Held by 229 ETFs
Biggest fund positions in ARDX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 19, 26 | Hohenleitner Susan | other | 11,537 |
| Nov 19, 26 | Reilly Joseph James | other | 3,755 |
| Nov 19, 26 | Bishop John E | other | 6,413 |
| Nov 19, 26 | Brady James Parker | other | 4,973 |
| Nov 19, 26 | Kelliher Mike | other | 7,319 |
| Nov 19, 26 | RAAB MICHAEL | other | 55,376 |
| Aug 21, 26 | Hohenleitner Susan | sell | 1,558 |
| Aug 21, 26 | Reilly Joseph James | sell | 2,872 |
| Aug 21, 26 | Reilly Joseph James | sell | 1,110 |
| Aug 21, 26 | Bishop John E | sell | 17,281 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ARDX coverage
Recent articles, reports, and earnings notes.
No research on ARDX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ARDX report →Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ARDX
prnewswire.com · Nov 16
ARDX DEADLINE TODAY: ROSEN, A LONGSTANDING LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important November 16 Deadline in Securities Class Action - ARDX
newsfilecorp.com · Nov 16
ARDELYX (NASDAQ: ARDX) CLASS ACTION DEADLINE TODAY: Faruqi & Faruqi, LLP Reminds Investors of November 16, 2026 Lead Plaintiff Deadline
businesswire.com · Nov 16
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
businesswire.com · Nov 16
Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
globenewswire.com · Nov 16
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
gurufocus.com · Nov 16
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
prnewswire.com · Nov 16
ARDX DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important November 16 Deadline in Securities Class Action - ARDX
globenewswire.com · Nov 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.